Board of Directors
Saundra Pelletier
Chief Executive Officer and interim Chair of the Board
Saundra Pelletier has served as Chief Executive Officer, President and Executive Director of Evofem Biosciences since February 2015, and as interim Chair of the Board since November 2021. Ms. Pelletier has led the company through its transition to the public market; the approval of PHEXXI® (lactic acid, citric acid, and potassium bitartrate), the first and only hormone-free, on-demand prescription contraceptive vaginal gel; the acquisition of SOLOSEC® (secnidazole) 2 g oral granules, an oral antibiotic approved to treat bacterial vaginosis and trichomoniasis with just one dose; and four consecutive years of net sales growth.
An expert in women’s health, Ms. Pelletier’s insight is driven by both intensive consumer research and deep commercial experience in the global markets with products addressing women’s health spanning every stage in their reproductive journey, from puberty to menopause. Her career in the pharmaceutical industry has spanned more than three decades, during which she has launched pharmaceutical brands worldwide and expanded indications for female healthcare brands in multiple countries. She is a published author, TEDx and keynote speaker, executive coach and staunch advocate for innovation in women’s healthcare.
Prior to Evofem, Ms. Pelletier was Executive Director at Woman Care Global, launching a sustainable supply chain providing access to reproductive healthcare in low- and middle-income countries. She started her career at G.D. Searle where during her eight year tenure she served in increasingly senior positions and ultimately as Global Franchise Leader.
Ms. Pelletier is a Director of Windtree Therapeutics, Inc. (Nasdaq: WINT) (biotechnology) and IMAC Holdings, Inc. (OTCQB: BACK) (proteomics and precision medicine). She also serves as an Advisory Board Member for several non-profit organizations including CEOs Against Cancer, Girls Inc., and The Center for Community Solutions.
Kim Kamdar, Ph.D.
Dr. Kamdar has served as a member of Evofem Biosciences’ board of directors since January 2018. Dr. Kamdar is a Managing Partner of Domain Associates, LLC, a life sciences venture capital firm, which she joined in 2005 and a Managing Partner of Medical Excellence Capital, LLC, since 2021.
Dr. Kamdar is current Chair of the board of directors of Seraphina Therapeutics, Inc., and Truvian Sciences. She also serves on the board of directors of Sera Prognostics (Nasdaq: SERA), Alume, Trotana, Recellience15, Pleno, and Savanna Biotherapeutics. Past investments include Ariosa (acquired by Roche), Corthera (acquired by Novartis), BiPar Sciences (acquire by Sanofi-Aventis) and Omniome (acquired by NASDAQ: PACB).
Formerly, Dr. Kamdar was a Kauffman Fellow with MPM Capital. Prior to joining MPM, She was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms. Dr. Kamdar is the author of ten papers as well as the inventor on seven patents. Dr. Kamdar received her B.A. from Northwestern University and Ph.D. in biochemistry and genetics from Emory University.
Dr. Kamdar serves as an advisory board member of Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine and is on the board of the La Jolla Institute of Immunology.
Tony O’Brien
Mr. O’Brien has served as a member of the Evofem Biosciences board of directors since January 2018. He is a Chartered Director (C.Dir) of the Institute of Directors UK and Ireland.
Mr. O’Brien served as the Director General of Ireland’s Health Service Executive (HSE), an organization responsible for the provision of health and personal social services for the residents of Ireland, from July 2012 to May 2018. Prior to his role as Director General, Mr. O’Brien was the Chief Operating Officer of the Department of Health’s Special Delivery Unit and a member of the Department’s Management Board. Mr. O’Brien previously served as Director of Clinical Strategy and Programs in the HSE and Chief Executive Officer of the National Treatment Purchase Fund.
Mr. O’Brien served as Chief Advisor to the HSE on the implementation of the National Cancer Control Strategy, Project Director for the National Plan for Radiation Oncology, and is a former Chairman of the National Cancer Registry Board.
Mr. O’Brien was the founding Chief Executive Officer of the National Cancer Screening Service from 2007 to May 2011, Director of BreastCheck, CervicalCheck, and an Associate and Interim Director of the National Cancer Control Programme.
Prior to joining the HSE, Mr. O’Brien served as Chief Executive of the Irish Family Planning Association and as the Chief Executive of the UK Family Planning Association.
Mr. O’Brien has significant experience of leadership roles in regulated sectors.
He is Board Chair at both Lotus Care (a registered provider of residential, care services for children with disabilities) and Voltson Limited (the holding company for AllView Healthcare, DermView, and OptaView). Mr. O’Brien is also a member of the Board of Lifeline Ambulance Service, Bartra Health, and Health Navigator (UK)
In the non-profit sector Mr. O’Brien serves as Chair of Safetynet Primary Care, a provider of medical services, including “street medicine,” to disadvantaged and marginalized persons. In May 2025 he was appointed Chair of one of Ireland’s leading homelessness charities, the Peter McVerry Trust. Additionally, Mr. O’Brien was appointed by the Government of Ireland as a member of the Policing and Community Safety Authority in April 2025.
Mr. O’Brien holds a Master of Sciences in Management Practice from Trinity College, University of Dublin. He is Adjunct Assistant Professor in Health Strategy and Management at Trinity College Dublin.
Lisa Rarick, MD
Dr. Rarick has served as a member of Evofem Biosciences’ board of directors since February 2020. Dr. Rarick is an obstetrician/gynecologist and regulatory affairs expert with 35 years’ experience in women’s health and 15 years’ experience leading several offices within the U.S. Food and Drug Administration (FDA).
Dr. Rarick began her career at the FDA in 1988 as a Medical Officer, responsible for the management of products indicated for a variety of reproductive health conditions including oral, transdermal, and vaginal contraceptives. She became the Director for the Division of Reproductive and Urologic Products (DRUP) when it was formed in 1996 and later held several management roles in the Center for Drug Evaluation and Research (CDER), including Deputy Director of the Office of Drug Evaluation II and Associate Director in the Office of the Center Director.
Her final year at the FDA was spent in the Office of Women’s Health, where she focused on HIV prevention, pregnancy prevention, pre- and post-pregnancy care, and menopausal therapy. She is currently a reproductive health and regulatory affairs consultant who has helped numerous companies navigate the development of their products from early-stage development through FDA approval.
Dr. Rarick received her B.S. and M.D. from the Loma Linda University School of Medicine and completed her residency training in Obstetrics and Gynecology at Georgetown University. She has been a member of the Scientific Advisory Committee for the National Institute of Child Health and Human Development since 2004 and served on the Board of Directors for Alliance Partners 360 from June 2017 to June 2019.
Colin Rutherford
Colin Rutherford has served as a member of Evofem Biosciences’ board of directors since 2017. He is an experienced public and private company chairman and independent director, with relevant sector experience including asset management, bioscience, leisure, and real estate.
In addition to Evofem, Mr. Rutherford currently serves on the boards of directors of several firms. He is Board Chair of Brookgate Limited (real estate development) and Rothley Group Limited, (private client legal services and claims management); Board member, Audit Committee Chair and SID-elect of New River REIT Plc, (LSE: NRR); and, Board member and Audit Committee Chair at Donaldson Group Limited (manufacturing). He also co-founded and has served as Chair of Act Blade Limited (wind energy blade manufacturing) since 2015, and since 2021 has been Chair of Allstone Group Limited (aggregates and waste recycling).
Mr. Rutherford previously served on the board of directors of companies including Hifas da Terra SA, a Spanish biopharma company; Meallmore Limited, a UK healthcare group; Right Group Limited, a recently-sold MIS/MPS distributor; Euro-Sales Plc, (sold to Royal Bank of Scotland); and, European Health Care Group (sold to two US-based hedge funds).
Early in his career, Mr. Rutherford co-founded Rutherford Manson Dowds (RMD), a UK corporate finance and full service accountancy firm. The firm was sold to Deloitte in 1999.
Mr. Rutherford earned a degree in Accountancy and Finance from Heriot Watt University, qualified with Touche Ross (now Deloitte) in 1984, and is a Harvard Business School alumnus. He is a Member of the Scottish Institute of Chartered Accountants.